ERBB2 and breast carcinoma: Our data demonstrate that constitutive ERK activation in the Her2-overexpressing breast cancer cells repressed the level of let-7f and that the inhibitory effect could be enhanced by the β2-AR agonist, indicating a novel mechanism of the β2-AR expression upregulation in Her2-overexpressing breast cancer.